CN1583131A - Frozen dry powder injection of composite salvia miltiorrhiza and its preparation - Google Patents
Frozen dry powder injection of composite salvia miltiorrhiza and its preparation Download PDFInfo
- Publication number
- CN1583131A CN1583131A CN 200410046126 CN200410046126A CN1583131A CN 1583131 A CN1583131 A CN 1583131A CN 200410046126 CN200410046126 CN 200410046126 CN 200410046126 A CN200410046126 A CN 200410046126A CN 1583131 A CN1583131 A CN 1583131A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- borneolum syntheticum
- extractum
- water
- adds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 57
- 239000007924 injection Substances 0.000 title claims abstract description 57
- 239000000843 powder Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 34
- 241000304195 Salvia miltiorrhiza Species 0.000 title 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 34
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 31
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 31
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 26
- 235000005412 red sage Nutrition 0.000 claims abstract description 20
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 116
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000011347 resin Substances 0.000 claims description 22
- 229920005989 resin Polymers 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- 239000012047 saturated solution Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- 238000000108 ultra-filtration Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 238000005202 decontamination Methods 0.000 claims description 7
- 230000003588 decontaminative effect Effects 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 235000017276 Salvia Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- 239000003957 anion exchange resin Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- -1 filter Substances 0.000 claims description 5
- 238000000703 high-speed centrifugation Methods 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 10
- 239000008899 fufang danshen Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 5
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 5
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 5
- 229960003371 protocatechualdehyde Drugs 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000002510 pyrogen Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 3
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229930183842 salvianolic acid Natural products 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920006221 acetate fiber Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100461269A CN100372525C (en) | 2004-06-01 | 2004-06-01 | Frozen dry powder injection of composite salvia miltiorrhiza and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100461269A CN100372525C (en) | 2004-06-01 | 2004-06-01 | Frozen dry powder injection of composite salvia miltiorrhiza and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1583131A true CN1583131A (en) | 2005-02-23 |
CN100372525C CN100372525C (en) | 2008-03-05 |
Family
ID=34601943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100461269A Expired - Lifetime CN100372525C (en) | 2004-06-01 | 2004-06-01 | Frozen dry powder injection of composite salvia miltiorrhiza and its preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100372525C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297278C (en) * | 2004-07-28 | 2007-01-31 | 广东天之骄生命科技有限公司 | Medicinal composition containing salvianolic acid B, total ara-saponin and camphol and its preparation and use |
CN1297279C (en) * | 2004-07-28 | 2007-01-31 | 广东天之骄生命科技有限公司 | Medicinal composition containing danshensu, total ara-saponin and camphol and its preparation and use |
CN101084998B (en) * | 2006-06-08 | 2011-10-26 | 天津天士力之骄药业有限公司 | Compound red sage root freezing-dried powder injection |
CN101084997B (en) * | 2006-06-08 | 2012-06-06 | 天津天士力之骄药业有限公司 | Traditional Chinese medicine freezing-dried powder injection for treating cardiovascular and cerebrovascular diseases and its preparing method |
CN102688426A (en) * | 2012-06-25 | 2012-09-26 | 许梅 | Traditional Chinese medicine composition for treating acute upper gastrointestinal hemorrhage, as well as preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1144673A (en) * | 1995-09-04 | 1997-03-12 | 张相国 | Red sage root and its composite compound red sage root powder injection and preparation method |
CN1202103C (en) * | 2002-05-23 | 2005-05-18 | 天津天士力制药股份有限公司 | Preparation method of red sageroot total phenolic acid and its use |
CN1422653A (en) * | 2002-11-09 | 2003-06-11 | 边冬梅 | Effective part of root of red-rooted salvia and compound powder injecta of root of red-rooted salvia and preparation method and use of said medicine |
-
2004
- 2004-06-01 CN CNB2004100461269A patent/CN100372525C/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1297278C (en) * | 2004-07-28 | 2007-01-31 | 广东天之骄生命科技有限公司 | Medicinal composition containing salvianolic acid B, total ara-saponin and camphol and its preparation and use |
CN1297279C (en) * | 2004-07-28 | 2007-01-31 | 广东天之骄生命科技有限公司 | Medicinal composition containing danshensu, total ara-saponin and camphol and its preparation and use |
CN101084998B (en) * | 2006-06-08 | 2011-10-26 | 天津天士力之骄药业有限公司 | Compound red sage root freezing-dried powder injection |
CN101084997B (en) * | 2006-06-08 | 2012-06-06 | 天津天士力之骄药业有限公司 | Traditional Chinese medicine freezing-dried powder injection for treating cardiovascular and cerebrovascular diseases and its preparing method |
CN102688426A (en) * | 2012-06-25 | 2012-09-26 | 许梅 | Traditional Chinese medicine composition for treating acute upper gastrointestinal hemorrhage, as well as preparation method and application thereof |
CN102688426B (en) * | 2012-06-25 | 2013-12-18 | 青岛华仁技术孵化器有限公司 | Traditional Chinese medicine composition for treating acute upper gastrointestinal hemorrhage, as well as preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100372525C (en) | 2008-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1164582C (en) | Process for preparing danshen salviandic acid | |
CN101049331A (en) | Preparation method for extracting purified general saponin from notoginseng of Chinese traditional medicine | |
CN101396384A (en) | Asiatic centella extract and preparation methode thereof | |
CN101057890A (en) | Traditional Chinese medicinal composition for treating coronary heart disease and its preparation method, preparations and its application | |
CN100372525C (en) | Frozen dry powder injection of composite salvia miltiorrhiza and its preparation | |
CN110194758B (en) | Method for separating and purifying aristolochic acid compounds from caulis Aristolochiae Manshuriensis | |
CN1297279C (en) | Medicinal composition containing danshensu, total ara-saponin and camphol and its preparation and use | |
CN1682971A (en) | Compound isatis root freeze-dried powder injection and its preparing method | |
CN1285344C (en) | Method for preparing acanthopanax injectio | |
CN101422529B (en) | Preparation method of traditional Chinese medicine preparation | |
CN1887324A (en) | Chinese composition and its prepn process and quality control method | |
CN1817360A (en) | Medicinal composition for treating acute and chronic congestive heart failure, its preparation and use | |
CN1911272A (en) | Powder injection contg. high content tanshin polyphenolic acid salts, and its prepn. method | |
CN1278703C (en) | Freeze-dried powder and injection preparation of red sage root and safflower, and preparation method | |
CN101422522B (en) | Preparation method of traditional Chinese medicine preparation | |
CN1220489C (en) | Freeze-dried Danhong powder injection for injection and its preparing method | |
CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
CN1546152A (en) | Freeze-dried 'Shenqifuzheng' powder for injection and its preparing process | |
CN1264506C (en) | Pharmaceutical combination containing red sage root element and preparation method thereof | |
CN1616064A (en) | Blood circulation promoting dripping pill for treating cardiocerebral vascular disease | |
CN1297278C (en) | Medicinal composition containing salvianolic acid B, total ara-saponin and camphol and its preparation and use | |
CN100346798C (en) | Traditional Chinese medicine active part composition for curing cardio and cerebral vascular disease and its preparing method | |
CN100518802C (en) | Extraction of effective parts for Danshen root and rhizoma chuanxiong | |
CN1234399C (en) | Method for preparing mailuoning freeze-dried powder for injection | |
CN1600357A (en) | Effective position of pilose asiabell root, preparation, medication use and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGDONG TIANZHIJIAO LIFE SCIENCE CO., LTD. Free format text: FORMER OWNER: SHENNONGTAN MEDICINE SCIENCE AND TECHNOLOGY CO., LTD., BEIJING Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Effective date: 20050422 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050422 Address after: Guangzhou City, Tianhe District province and Guangdong Forest Road No. 150, Tianyu Garden Plaza Accord Room 802 Applicant after: GUANGDONG TIANZHIJIAO LIFE SCI Co-applicant after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: Room 1, 1803 door, building 1, Lianhua District, Beijing, Haidian District Applicant before: SHENNONGTAN MEDICINE SCIENCE T |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN TASLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: GUANGDONG TIANZHIJIAO LIFE SCIENCE CO., LTD. Effective date: 20090724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090724 Address after: Hedong District of Beichen Puji road in Tianjin No. 2 the modern Chinese medicine city zip code: 300410 Patentee after: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Address before: 802, room 510610, Tianyu garden, 150 Lin and Zhong Road, Tianhe District, Guangzhou, Guangdong. Zip code: 510610 Co-patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. Patentee before: GUANGDONG TIANZHIJIAO LIFE SCI |
|
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20080305 |
|
CX01 | Expiry of patent term |